The Novel Targets in the Ovarian Cancer Treatment Paradigm publication covers some of the latest practice-changing advances as it relates to novel targets in the treatment for patients with advanced ovarian cancer.
Evolving Technology Behind ADCs Could Improve Benefit in Advanced Ovarian Cancer
March 11th 2022Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.
Upifitamab Rilsodotin Has Potential to Address Unmet Need in Recurrent Ovarian Cancer
January 31st 2022Bradley J. Monk, MD, FACS, FACOG, discusses the unmet needs for patients with ovarian cancer and the clinical trials that seeking to address those needs, including the ADC upifitamab rilsodotin.